Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
It is almost ten years since the Banerjee 2009 report established that inappropriate prescribing of antipsychotics in the elderly was occurring in the UK and such patients had an 85% increased risk of adverse events and greater mortality. This report was a critical analysis addressing the outcomes of treatment practices for dementia in UK patients and globally, aimed at reducing prescribing of antipsychotic drugs for dementia. Since 2009, many significant studies worldwide (including several more recent large retrospective studies) provide more extensive longitudinal data for the adverse impacts of antipsychotic drugs in dementia. We have used the data in these studies including from over 380,000 dementia patients, with 85,069 prescribed antipsychotic agents as well as from 359,235 non-dementia antipsychotic drug users to provide an up-dated meta-analysis. This is the first meta-analysis to include evidence from general mental health studies showing that antipsychotic drugs precipitate excessive mortality across the spectrum. Prescribing of antipsychotic drugs for dementia or for other mental health care should be avoided and alternative means sought for handling behavioral disorders of such patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Research has shown that antipsychotics are associated with an increased risk of stroke and death in individuals with dementia.56,57”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [56]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“About one‐quarter of people with dementia have problems sleeping, and the problems can worsen as the disease progresses.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [68]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Hunter, J., & Schmidt, F. (2004) · doi:10.4135/9781412985031 · Cited by 3,023
Fixed-and random-effects models in meta-analysis.
Hedges, L. V., & Vevea, J. L. (1998) · Psychological Methods · doi:10.1037/1082-989x.3.4.486 · Cited by 2,977 · cited 3×
“In addition, the Hedges and Vevea [31] as well as the Hunter and Schmidt [30] methods for calculating the pooled estimate from the 20 studies were compared, giving similar point effect sizes for the pooled HR, 2.”
MethodInfluentialPeters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R., & Rushton, L. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.010 · Cited by 2,053
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa‐Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., et al. (2017) · World Psychiatry · doi:10.1002/wps.20420 · Cited by 1,729
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 2×
“In 2005, based on the published greater risk of cerebrovascular events (with risperidone, olanzapine, and aripiprazole) from meta-analysis of 17 randomized placebo controlled trials, the Federal Food and Drug Administration (FDA) in the USA noted that such atypical antipsychotics were associated with a 60–70% increase…”
BackgroundResultEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206 · cited 1×
“Worldwide, many similar studies over 2005–2009 were reported contraindicating use of antipsychotic drugs for dementia, with the majority clearly establishing and raising a serious red flag regarding their drug safety and adverse effects [9, 10, 12, 13, 20, 21].”
ResultAtypical antipsychotic drugs and the risk of sudden cardiac death
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194 · cited 7×
“This study compared those prescribed the atypical antipsychotics (risperidone (n = 4,406), olanzapine (n = 1,563), quetiapine (n = 497), and clozapine (n = 58) and 3,205 new users of conventional antipsychotics (haloperidol (n = 1,413), phenothiazines (including thioridazine [n = 546], perphenazine [n = 314], promazin…”
BackgroundResultInfluentialField, A. P., & Gillett, R. (2010) · British Journal of Mathematical and Statistical Psychology · doi:10.1348/000711010x502733 · Cited by 1,162 · cited 4×
“Sample Correlation Variance = 0.0191 Sampling Error Variance = 0.0000 Estimated Variance in Population Correlations = 0.0191 SPS 24.0 Syntax based on the macro of Field and Gillett [35]. to the point that they are no longer representative and result in greatly reduced numbers of patients (one with less than 16 subject…”
BackgroundMethodInfluentialPatsopoulos, N. A., Evangelou, E., & Ioannidis, J. P. (2008) · International Journal of Epidemiology · doi:10.1093/ije/dyn065 · Cited by 1,138
Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications
Wang, P. S., Schneeweiss, S., Avorn, J., Fischer, M. A., Mogun, H., Solomon, D. H., & Brookhart, M. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052827 · Cited by 959 · cited 3×
“In 2005, based on the published greater risk of cerebrovascular events (with risperidone, olanzapine, and aripiprazole) from meta-analysis of 17 randomized placebo controlled trials, the Federal Food and Drug Administration (FDA) in the USA noted that such atypical antipsychotics were associated with a 60–70% increase…”
BackgroundResultAntipsychotic Drug Use and Mortality in Older Adults with Dementia
Gill, S. S., Bronskill, S. E., Normand, S.-L. T., Anderson, G. M., Sykora, K., Lam, K., Bell, C. M., Lee, P. E., Fischer, H. D., Herrmann, N., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-11-200706050-00006 · Cited by 624 · cited 2×
“Worldwide, many similar studies over 2005–2009 were reported contraindicating use of antipsychotic drugs for dementia, with the majority clearly establishing and raising a serious red flag regarding their drug safety and adverse effects [9, 10, 12, 13, 20, 21].”
ResultMaust, D. T., Kim, H. M., Seyfried, L. S., Chiang, C., Kavanagh, J., Schneider, L. S., & Kales, H. C. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.3018 · Cited by 617 · cited 2×
“for 90,786 dementia patients age 65 and older [54].”
BackgroundInfluentialBallard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Page, A. T., Clifford, R. M., Potter, K., Schwartz, D., & Etherton‐Beer, C. D. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12975 · Cited by 496
Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Sheehan, R., Hassiotis, A., Walters, K., Osborn, D., Strydom, A., & Horsfall, L. (2015) · BMJ · doi:10.1136/bmj.h4326 · Cited by 403 · cited 2×
“in 2015 [5] from the UK showed that the number”
BackgroundRisk of Mortality Among Individual Antipsychotics in Patients With Dementia
Kales, H. C., Kim, H. M., Zivin, K., Valenstein, M., Seyfried, L. S., Chiang, C., Cunningham, F., Schneider, L. S., & Blow, F. C. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11030347 · Cited by 384 · cited 1×
“24 compared to risperidone), but decreased significantly and sharply thereafter [8] confirming the earlier reports [53].”
ResultSchneeweiss, S., Setoguchi, S., Brookhart, A., Dormuth, C., & Wang, P. S. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.061250 · Cited by 366 · cited 2×
“Worldwide, many similar studies over 2005–2009 were reported contraindicating use of antipsychotic drugs for dementia, with the majority clearly establishing and raising a serious red flag regarding their drug safety and adverse effects [9, 10, 12, 13, 20, 21].”
ResultACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia
Jeste, D. V., Blazer, D., Casey, D., Meeks, T., Salzman, C., Schneider, L., Tariot, P., & Yaffe, K. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301492 · Cited by 365
Sultzer, D. L., Davis, S. M., Tariot, P. N., Dagerman, K. S., Lebowitz, B. D., Lyketsos, C. G., Rosenheck, R. A., Hsiao, J. K., Lieberman, J. A., Schneider, L. S., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111779 · Cited by 321
Huybrechts, K. F., Gerhard, T., Crystal, S., Olfson, M., Avorn, J., Levin, R., Lucas, J. A., & Schneeweiss, S. (2012) · BMJ · doi:10.1136/bmj.e977 · Cited by 266 · cited 1×
“Antipsychotic HR = 2.07; [1.89–2.26] Huybrechts et al., 2012 [7] 6-month follow-up Haloperidol compared to risperidone Dept. Veteran Affairs 1999–2008 33,604 ≥65 years All-cause mortality in dementia patients.”
BackgroundInfluentialDeprescribing in Frail Older People: A Randomised Controlled Trial
Potter, K., Flicker, L., Page, A., & Etherton-Beer, C. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149984 · Cited by 246 · cited 1×
“De-prescribing is likely to be highly beneficial, as has been supported by systematic review and meta-analysis [86–88] as well as by a recent randomized trial which showed no significant adverse effects on survival or other clinical outcomes after de-prescribing elderly patients in aged care [89].”
ResultJackson, D., Bowden, J., & Baker, R. (2010) · Journal of Statistical Planning and Inference · doi:10.1016/j.jspi.2009.09.017 · Cited by 226 · cited 2×
“The DerSimonian and Laird procedure is the simplest, most commonly used method for fitting the random effects model [29] and the pooled results (HR = 1.”
MethodSerious Cardiovascular Events and Mortality Among Patients with Schizophrenia
Enger, C., Weatherby, L., Reynolds, R. F., Glasser, D. B., & Walker, A. M. (2004) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000105996.62105.07 · Cited by 215
Atypical Antipsychotic Use in Patients With Dementia: Managing Safety Concerns
Steinberg, M., & Lyketsos, C. G. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12030342 · Cited by 209
Declercq, T., Petrovic, M., Azermai, M., Vander Stichele, R., De Sutter, A. I., van Driel, M. L., & Christiaens, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007726.pub2 · Cited by 206
Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease
Devanand, D. P., Mintzer, J., Schultz, S. K., Andrews, H. F., Sultzer, D. L., de la Pena, D., Gupta, S., Colon, S., Schimming, C., Pelton, G. H., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114058 · Cited by 195
Farrell, B., Tsang, C., Raman-Wilms, L., Irving, H., Conklin, J., & Pottie, K. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122246 · Cited by 178 · cited 1×
“In summary from the global evidence, it is clear that valuable lessons can be learned from the mistakes made over the past decades, and since the 2009 Banerjee report [3] calling for solutions to the problem of overprescribing antipsychotic drugs for dementia and the best way to enforce changes in practice [76].”
BackgroundBallard, C., Creese, B., Corbett, A., & Aarsland, D. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.506711 · Cited by 139 · cited 1×
“However, of greater concern was the significantly increased mortality after continued longer term use at the 2 (46% survival only versus 71% in the control) and 3-year (30% survival only versus 59% in the control) follow-up time points [90, 91].”
BackgroundClinical practice guidelines for dementia in Australia
Laver, K., Cumming, R. G., Dyer, S. M., Agar, M. R., Anstey, K. J., Beattie, E., Brodaty, H., Broe, T., Clemson, L., Crotty, M., et al. (2016) · Medical Journal of Australia · doi:10.5694/mja15.01339 · Cited by 134 · cited 4×
“As part of the ‘PRIME’ study, 779 community based dementia patients across Australia were enrolled at baseline and observed with follow-up for three years with mortality determined at eight years [51].”
BackgroundInfluentialLopez, O. L., Becker, J. T., Chang, Y.-F., Sweet, R. A., Aizenstein, H., Snitz, B., Saxton, J., McDade, E., Kamboh, M. I., DeKosky, S. T., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12081046 · Cited by 129 · cited 1×
“The three highly heterogeneous studies in [28] were likely flawed by design because of only small dementia patient sample sizes [61, 75], or they concerned mild to moderate dementia patients in outpatient settings [62], not advanced/elderly patients residing in nursing homes.”
BackgroundPrescription Opioids and Risk of Dementia or Cognitive Decline: A Prospective Cohort Study
Dublin, S., Walker, R. L., Gray, S. L., Hubbard, R. A., Anderson, M. L., Yu, O., Crane, P. K., & Larson, E. B. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13562 · Cited by 121
The spurious advance of antipsychotic drug therapy
Tyrer, P. J., & Kendall, T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61765-1 · Cited by 119
Ma, H., Huang, Y., Cong, Z., Wang, Y., Jiang, W., Gao, S., & Zhu, G. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140579 · Cited by 109
Liperoti, R., Onder, G., Landi, F., Lapane, K. L., Mor, V., Bernabei, R., & Gambassi, G. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04597yel · Cited by 103 · cited 1×
“HR = 1.26; [1.13–1.42] Liperoti et al., 2009 [6] 6-month follow-up Except quetiapine or olanzapine cf’d risperdone.”
BackgroundInfluentialRaivio, M. M., Laurila, J. V., Strandberg, T. E., Tilvis, R. S., & Pitkälä, K. H. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31802d0b00 · Cited by 99
Jensen-Dahm, C., Gasse, C., Astrup, A., Mortensen, P. B., & Waldemar, G. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.013 · Cited by 96
Risk of cerebrovascular events in elderly users of antipsychotics
Kleijer, B., van Marum, R., Egberts, A., Jansen, P., Knol, W., & Heerdink, E. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093583 · Cited by 96 · cited 1×
“commencing antipsychotics in elderly patients [4].”
Langballe, E. M., Engdahl, B., Nordeng, H., Ballard, C. G., Aarsland, D., & Selbæk, G. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.06.007 · Cited by 93 · cited 2×
“HR30days = 2.1 [1.6–2.9] Langballe et al., 2014 [42] HR730-2,400days = 1.7 [1.6–1.9].”
BackgroundInfluentialVilalta-Franch, J., Calvó-Perxas, L., Garre-Olmo, J., Turró-Garriga, O., & López-Pousa, S. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120913 · Cited by 90 · cited 1×
“The three highly heterogeneous studies in [28] were likely flawed by design because of only small dementia patient sample sizes [61, 75], or they concerned mild to moderate dementia patients in outpatient settings [62], not advanced/elderly patients residing in nursing homes.”
BackgroundPsychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA
Maust, D. T., Langa, K. M., Blow, F. C., & Kales, H. C. (2017) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4452 · Cited by 83 · cited 1×
“…2000–2011 45,894 Alzheimer’s Dementia patients All-cause Mortality in Dementia patients: Antipsychotics: Atypical and Typical Current antipsychotic users (prior 12 months) HR = 2.31; [2.14–2.49], p < 0.001 Nielsen et al., 2017 [44] Cardiovascular, infection, cancer ATC Code = N05A except Lithium.”
BackgroundInfluentialPredictors of Mortality in Dementia: The PRIME Study
Connors, M. H., Ames, D., Boundy, K., Clarnette, R., Kurrle, S., Mander, A., Ward, J., Woodward, M., & Brodaty, H. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150946 · Cited by 81 · cited 1×
“Mostly >65 years follow-up 3 years with mortality determined at 8 years Atypical antipsychotic drugs versus non-users Atypical HR = 1.61; [1.29–2.02] (p < 0.01) Connors et al., 2016 [51] (Continued) Table 1 (Continued) Country Study/Years Patient No.”
BackgroundInfluentialTaipale, H., Koponen, M., Tanskanen, A., Tolppanen, A.-M., Tiihonen, J., & Hartikainen, S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.10.004 · Cited by 73 · cited 1×
“Despite the extensive evidence that these drugs increase all-cause mortality in dementia and other patients, they remain commonly overprescribed and in some countries have seen little to no change in use or in many cases have been increasingly prescribed over the past 10 years, even for long term use and regardless of…”
BackgroundMurray-Thomas, T., Jones, M. E., Patel, D., Brunner, E., Shatapathy, C. C., Motsko, S., & Van Staa, T. P. (2013) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2013/247486 · Cited by 72 · cited 8×
“Omitting all three (Jones [36, 37], Jennum [43], and Koponen [22]) studies lowered these heterogeneity values to Q = 32.”
BackgroundResultInfluentialBrett, J., Karanges, E. A., Daniels, B., Buckley, N. A., Schneider, C., Nassir, A., Zoega, H., McLachlan, A. J., & Pearson, S.-A. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867417721018 · Cited by 70 · cited 1×
“5% of single antipsychotic prescriptions being for haloperidol [83].”
BackgroundRossom, R. C., Rector, T. S., Lederle, F. A., & Dysken, M. W. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02873.x · Cited by 69 · cited 5×
“…Texas Antipsychotics dementia users versus non-user control N = 8,867–32,996 All-cause mortality, 5-year follow-up Antipsychotics 30 day first use: Rossom et al., 2010 [53] ≥65 years old Haloperidol, 2,217 HR = 3.2; [2.2–4.5], p < 0.001Quetiapine, 4,277 HR = 1.2; [0.7–1.8], p = 0.5 Olanzapine,…”
BackgroundResultInfluentialHulshof, T. A., Zuidema, S. U., Ostelo, R., & Luijendijk, H. J. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.03.015 · Cited by 64
Simoni-Wastila, L., Ryder, P. T., Qian, J., Zuckerman, I. H., Shaffer, T., & Zhao, L. (2009) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31819b8936 · Cited by 63
Antipsychotic Drug Use and the Risk of Seizures: Follow-up Study with a Nested Case–Control Analysis
Bloechliger, M., Rüegg, S. J., Jick, S. S., Meier, C. R., & Bodmer, M. (2015) · CNS Drugs · doi:10.1007/s40263-015-0262-y · Cited by 62 · cited 1×
“…dementia patients First-time seizures in Dementia patients over 15-year period Atypical antipsychotics Olanzapine, quetiapine *HR = 2.335 [1.35–4.01] Bloechliger et al., 2015 [38] Low-to-medium potency typical antipsychotics HR = 3.01 [1.34–6.64] [38] Medium-to-high potency typical…”
BackgroundInfluentialAripiprazole in the treatment of Alzheimer's disease
De Deyn, P. P., Drenth, A. F., Kremer, B. P., Oude Voshaar, R. C., & Van Dam, D. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.764989 · Cited by 61
Pitkälä, K. H., Juola, A.-L., Hosia‐Randell, H., Teramura-Grönblad, M., Soini, H., Savikko, N. M., & Bell, J. S. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.06.009 · Cited by 57
Jennum, P., Baandrup, L., Ibsen, R., & Kjellberg, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.08.014 · Cited by 55 · cited 9×
“Omitting all three (Jones [36, 37], Jennum [43], and Koponen [22]) studies lowered these heterogeneity values to Q = 32.”
BackgroundResultInfluentialSuh, G.-H., & Shah, A. (2005) · International Psychogeriatrics · doi:10.1017/s1041610205002243 · Cited by 55 · cited 1×
“The three highly heterogeneous studies in [28] were likely flawed by design because of only small dementia patient sample sizes [61, 75], or they concerned mild to moderate dementia patients in outpatient settings [62], not advanced/elderly patients residing in nursing homes.”
BackgroundLucas, J. A., & Bowblis, J. R. (2017) · Health Affairs · doi:10.1377/hlthaff.2016.1439 · Cited by 55
Dennis, M., Shine, L., John, A., Marchant, A., McGregor, J., Lyons, R. A., & Brophy, S. (2017) · Neurology and Therapy · doi:10.1007/s40120-016-0060-6 · Cited by 54 · cited 2×
“Dennis et al., 2017 [40]Atypical 1687 France 16 French Memory Centres 534 Alzheimer’s Dementia patients, 102 new users All-cause Mortality in Alzheimer’s dementia 3.5-year follow-up Antipsychotics (typical and atypical) new use versus non-user control HR = 1.93; [1.15–3.25] Gardette et al., 2012…”
BackgroundInfluentialMusicco, M., Palmer, K., Russo, A., Caltagirone, C., Adorni, F., Pettenati, C., & Bisanti, L. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000326213 · Cited by 50 · cited 1×
“cal (n = 156) versus atypical (n = 806) antipsychotic drugs and their effects on mortality over a two year follow up since dementia diagnosis [48].”
BackgroundJones, M. E., Campbell, G., Patel, D., Brunner, E., Shatapathy, C. C., Murray-Thomas, T., van Staa, T. P., & Motsko, S. (2013) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2013/647476 · Cited by 46 · cited 10×
“Omitting all three (Jones [36, 37], Jennum [43], and Koponen [22]) studies lowered these heterogeneity values to Q = 32.”
BackgroundResultInfluentialGardette, V., Lapeyre‐Mestre, M., Coley, N., Cantet, C., Montastruc, J., Vellas, B. J., & Andrieu, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512803569037 · Cited by 46 · cited 2×
“…Alzheimer’s Dementia patients, 102 new users All-cause Mortality in Alzheimer’s dementia 3.5-year follow-up Antipsychotics (typical and atypical) new use versus non-user control HR = 1.93; [1.15–3.25] Gardette et al., 2012 [41] (Continued) Table 1 (Continued) Country Study/Years Patient No.”
BackgroundMethodInfluentialJackson, J. W., Schneeweiss, S., VanderWeele, T. J., & Blacker, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105376 · Cited by 40
Antipsychotic Drug Interactions and Mortality Among Nursing Home Residents With Cognitive Impairment
Liperoti, R., Sganga, F., Landi, F., Topinková, E., Denkinger, M. D., van der Roest, H. G., Foebel, A. D., Finne‐Soveri, H., Bernabei, R., & Onder, G. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10303 · Cited by 40 · cited 2×
“HR = 1.71; [1.15–2.54] Liperoti et al., 2017 [23] Australia Nationwide memory clinics Community based dementia patients 779.”
BackgroundMethodInfluentialZhai, Y., Song, Y., & Zhang, D. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151207 · Cited by 39 · cited 9×
“Added to this, since [28] was published, several much larger and longer term studies have recently emerged.”
BackgroundMethodInfluentialKoponen, M., Taipale, H. T., Lavikainen, P., Tanskanen, A. J., Tiihonen, J., Tolppanen, A., Ahonen, R. S., & Hartikainen, S. A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160671 · Cited by 39 · cited 4×
“Koponen et al., 2017 [46] Median follow-up 2.5 years (HR1-30days = 1.74 to HR30-90days = 2.11).”
BackgroundResultInfluentialThe antipsychotic story: changes in prescriptions and overdose without better safety
Berling, I., Buckley, N. A., & Isbister, G. K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12927 · Cited by 37 · cited 1×
“Disturbingly, increased prescribing of antipsychotic drugs has been reported [82], including a doubling in prescriptions over the period from 2007 to 2015 within Australia, predominantly with 47.”
BackgroundDong, X. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13538 · Cited by 36
Koponen, M., Taipale, H. T., Tanskanen, A. J., Tolppanen, A., Tiihonen, J., Ahonen, R. S., & Hartikainen, S. A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.008 · Cited by 35
Association of a Communication Training Program With Use of Antipsychotics in Nursing Homes
Tjia, J., Hunnicutt, J. N., Herndon, L., Blanks, C. R., Lapane, K. L., & Wehry, S. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.0746 · Cited by 35 · cited 5×
“This has led to the need for change in the current practice for dealing with BPSD by using the antipsychotic drugs as chemical restraints.”
BackgroundInfluentialArai, H., Nakamura, Y., Taguchi, M., 小林, 啓., Yamauchi, K., Schneider, L. S. S., & J‐CATIA Study Group (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.03.006 · Cited by 33 · cited 3×
“very short periods [47], whereas the longer-term users”
BackgroundInfluentialRalph, S. J., & Espinet, A. J. (2017) · Dementia · doi:10.1177/1471301217746769 · Cited by 29
Self-citationPiersanti, M., Capannolo, M., Turchetti, M., Serroni, N., Berardis, D. D., Evangelista, P., Costantini, P., Orsini, A., Rossi, A., & Maggio, R. (2014) · Rivista di psichiatria · doi:10.1708/1407.15623 · Cited by 27 · cited 3×
“Quetiapine was the most commonly prescribed drug and increasing doses of this drug significantly correlated with increased mortality rates, up to 40% with the highest dose and most of these within the 4 months since last treatment [49].”
BackgroundInfluentialTaipale, H., Koponen, M., Tanskanen, A., Lavikainen, P., Tolppanen, A.-M., Sund, R., Tiihonen, J., & Hartikainen, S. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000161 · Cited by 27
Nielsen, R. E., Lolk, A., Valentin, J. B., & Andersen, K. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12614 · Cited by 25 · cited 5×
“ish nationwide registries reported in 2016 [44] and”
BackgroundInfluentialNielsen, R. E., Lolk, A., Rodrigo-Domingo, M., Valentin, J. B., & Andersen, K. (2016) · European Psychiatry · doi:10.1016/j.eurpsy.2016.11.013 · Cited by 25 · cited 3×
“2017 [26], the mortality rates of 45,894 Alzheimer’s”
BackgroundInfluentialJackson, J. W., VanderWeele, T. J., Viswanathan, A., Blacker, D., & Schneeweiß, S. (2014) · American Journal of Epidemiology · doi:10.1093/aje/kwu210 · Cited by 22
Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia
Yohanna, D., & Cifu, A. S. (2017) · JAMA · doi:10.1001/jama.2017.11112 · Cited by 22 · cited 4×
“The recently published clinical practice guidelines for dementia in Australia [80] and by the American Psychiatric Association (APA) in the USA [81] are a step forward, but on the basis of the facts presented from the comprehensive international range of sources and assessments as reviewed here, will unlikely have the…”
BackgroundInfluentialSimoni‐Wastila, L., Wei, Y. J., Lucas, J. A., Brandt, N., Moyo, P., HUANG, T.-Y. J., Franey, C. S., & Harris, I. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14111 · Cited by 20
Psychotropic drug use and mortality in old people with dementia: investigating sex differences
Brännström, J., Boström, G., Rosendahl, E., Nordström, P., Littbrand, H., Lövheim, H., & Gustafson, Y. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0142-9 · Cited by 20 · cited 1×
“In addition, little benefit arises from studies where the mean age is close to 90, because such patients are too frail and impending death rates are consequently in the extreme (close to 50%) in both user and non-user groups, obscuring any drug-related effects [67].”
BackgroundSelbæk, G., Aarsland, D., Ballard, C. G., Engedal, K., Langballe, E. M., Benth, J. Š., & Bergh, S. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.01.016 · Cited by 16
Luijendijk, H. J., Bruin, N. C. D., Hulshof, T. A., & Koolman, X. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3912 · Cited by 15 · cited 1×
“However, the latter studies have been based on older literature or culminated from extracting heavily selected and refined data, adjusted by many exclusions made for clinical factors deemed as confounders such as mortality risks and co-morbidities relating to terminal illness [65].”
BackgroundChan, T.-C., Luk, J. K.-H., Shea, Y. F., Lau, K.-H., Chan, F. H.-W., Yu, G. K.-K., & Chu, L. (2011) · International Psychogeriatrics · doi:10.1017/s104161021100175x · Cited by 14
Gisev, N., Hartikainen, S. A., Chen, T. F., Korhonen, M., & Bell, J. S. (2012) · International Psychogeriatrics · doi:10.1017/s1041610212000117 · Cited by 13 · cited 2×
“5% with dementia) who were followed over 2000–2008, including 332 new users of antipsychotic drugs [45].”
BackgroundInfluentialShin, J., Choi, N., Lee, J., Park, M.-J., Lee, S. H., & Park, B. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115578162 · Cited by 13
Blaakilde, A. L. (2017) · European Journal of Cultural Studies · doi:10.1177/1367549417708437 · Cited by 12
Wang, L., Lee, S.-Y., Yuan, S.-S., Yang, K., Yang, C.-J., Lee, T., & Shyu, Y. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000451 · Cited by 11 · cited 1×
“…1996–2011 All-cause Mortality follow up varied from 2–6 years Typical Antipsychotics Chlorpromazine (2133) New users <30 day, 30–90 day and >90 days Wang et al., 2016 [72] Haloperidol (4454) Haloperidol HR30 = 2.11; [1.87–2.39], risperidone HR30 = 1.79; [1.45–2.22] relative to chlorpromazine…”
BackgroundInfluentialMortality Rates in Users of Typical and Atypical Antipsychotics: A Database Study in Poland
Zagożdżon, P., Goyke, B., & Wrotkowska, M. (2016) · Drugs - Real World Outcomes · doi:10.1007/s40801-016-0084-3 · Cited by 11
Psychoactive prescribing for older people—what difference does 15 years make?
Hughes, L. D., Cochrane, L., McMurdo, M. E. T., & Guthrie, B. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4288 · Cited by 10 · cited 1×
“Despite the extensive evidence that these drugs increase all-cause mortality in dementia and other patients, they remain commonly overprescribed and in some countries have seen little to no change in use or in many cases have been increasingly prescribed over the past 10 years, even for long term use and regardless of…”
BackgroundAntipsychotic prescription and mortality in hospitalized older persons
Chiesa, D., Marengoni, A., Nobili, A., Tettamanti, M., Pasina, L., Franchi, C., Djade, C. D., Corrao, S., Salerno, F., Marcucci, M., et al. (2017) · Psychogeriatrics · doi:10.1111/psyg.12263 · Cited by 10 · cited 2×
“In 2017, a study analyzed the REPOSI (Registro Politerapie Società Italiana Medicina Interna) database (≥65 years; mean age ∼80 years) from 80 internal medicine and geriatric wards in Italy from 2010 to 2012 for patients mainly with dementia, of which 135 were new antipsychotic drug users as hospitalized in-patients w…”
BackgroundMethodInfluentialBain, K. T., Schwartz, E. J., & Chan-Ting, R. (2017) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2017.090 · Cited by 8
Haloperidol Clearly Is Neurotoxic. Should It Be Banned
Nasrallah, H. A. (2013) · Current psychiatry · Cited by 6
Risk excess of mortality and use of antipsychotics: a case–noncase study
Arias, L. H. M., Lobato, C. T., García, S. P., Sáinz-Gil, M., Fadrique, R. S., & Ortega, P. G. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000146 · Cited by 5 · cited 7×
“All users versus users of other drugs Antipsychotics versus any other drugs as control Atypical antipsychotics Martin Arias et al., 2017 [24] HR = 2.47; [2.10–2.92] Typical antispychotics HR = 1.79; [1.47–2.18] Particularly: zuclopenthixol (HR = 3.39; [1.75–6.59]) risperidone HR = 2.07; [1.56–2.75) Haloperidol HR = 2.…”
BackgroundResultInfluentialEstimating Mortality Associated With Antipsychotics and Other Psychotropics—Reply
Maust, D. T., Schneider, L. S. S., & Kales, H. C. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0675 · Cited by 3 · cited 1×
“Maust et al., 2015 [54, 55] 6-month follow-up Atypical antipsychotics (olanzapine, quetiapine, and risperidone) dose-response increase in mortality risk, HR = 1.035; [1.005–1.065]; p = 0.02 in the high-dose subgroup relative to the low-dose group.”
BackgroundInfluential
Research works printed but not linked: 1
- BanerjeeS (2009) The use of antipsychotic medication for people with dementia: Time for action. Department of Health UK Government, London.
Cited by
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
2022 Alzheimer's disease facts and figures
(2022) · Alzheimer's & Dementia · doi:10.1002/alz.12638 · Cited by 2,341
2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Metadata
- Authors
- Ralph, S. J., & Espinet, A. J.
- Affiliations
- Griffith University (AU)
- Corresponding author
- Ralph, Stephen J.
- ORCID
- Ralph, Stephen J.
- Venue
- Journal of Alzheimer's Disease Reports
- Publisher
- SAGE Publications
- Published
- 2018-02-02
- Volume
- 2
- Issue
- 1
- Pages
- 1-26
- ISSN
- 2542-4823 (ISSN-L)
- PMC
- PMC6159703
- OpenAlex
- W2786890905
- Cited by
- 160
- References
- 93
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 21 · 2023: 21 · 2022: 35 · 2021: 26 · 2020: 17 · 2019: 10 · 2018: 6
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (unspecified)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Alzheimer s Disease Reports (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Griffith Research Online (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- antipsychotic drugs, all-cause mortality, dementia, inappropriate prescribing, elderly patients, behavioral and psychological symptoms of dementia, adverse drug reactions, prescribing patterns
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.